On March 26, 2025 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that an abstract containing preclinical data for KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI), in combination with cabozantinib, a tyrosine kinase inhibitor (TKI), in clear cell renal cell carcinoma (ccRCC), has been accepted for an oral presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Chicago, IL on April 28, 2025 (Press release, Kura Oncology, MAR 26, 2025, View Source [SID1234651461]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The latest findings for our next-generation farnesyl transferase inhibitor, KO-2806, being presented at this year’s AACR (Free AACR Whitepaper) Annual Meeting, add to the growing body of data demonstrating the potential of FTIs as companion therapeutic agents to augment the antitumor activities of various targeted therapies and to overcome resistance in combination," said Francis Burrows, Ph.D., Chief Scientific Officer of Kura Oncology. "We continue to make good progress in our FIT-001 trial evaluating KO-2806 in solid tumor indications where there is unmet medical need, and we look forward to presenting the first clinical data for KO-2806 as monotherapy and in combination with cabozantinib for the treatment of RCC later this year."
The title and session information for the oral presentation are listed below. Full abstract details including title and text are currently available to registrants via the AACR (Free AACR Whitepaper) online itinerary planner. Details of the oral presentation, entitled "Farnesyl transferase inhibitor KO-2806 enhances the antitumor activity of cabozantinib in ccRCC tumors that progress on anti-VEGFR agents" (oral 6370), are as follows:
Session Date and Time: Monday, April 28, 2025; 2:30 PM – 4:45 PM CT
Session Title: Minisymposium Novel Antitumor Agents
Presentation Time: 4:25 PM – 4:40 PM CT
A copy of the presentation will be available in the Posters and Presentations section on Kura’s website at the beginning of the presentation session.